Qiagen's Alacris Investment Provides Biomarker Pipeline for PCR-Based MDx Assay Panels
January 13, 2011
Qiagen's Alacris Investment Provides Biomarker Pipeline for PCR-Based MDx Assay Panels
As part of its investment in Alacris, Qiagen receives an exclusive option to license biomarkers identified through the company's genomics data-analysis platform and develop them into PCR-based assays for use in molecular diagnostic and theranostic applications or biomedical research.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen Q4, 2012 Growth Driven Significantly by QiaSymphony Sales in MDx, Applied Markets
January 31, 2013 / PCR Insider - IntelligentMDx Developing Assays for Qiagen's QIAsymphony RGQ
January 7, 2013 / GenomeWeb Daily News - UPDATE: Qiagen Q2 Revenues Bounce 9 Percent; Plans to Buy Back $100M in Shares
July 25, 2012 / GenomeWeb Daily News - Qiagen Details Role of Recent Acquisitions, Agreements in Molecular Dx Business
February 11, 2010 / PCR Insider - Qiagen Closes $90M Purchase of SABiosciences, Promises 'Quick and Smooth' Integration
December 17, 2009 / PCR Insider